Get the Stockscreener App
19.52
3.23%
0.61
Pre-market:
18.87
-0.65
-3.33%
Celldex Therapeutics Inc stock is traded at $19.52, with a volume of 642.55K.
It is up +3.23% in the last 24 hours and up +29.02% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$18.91
Open:
$18.73
24h Volume:
642.55K
Relative Volume:
0.85
Market Cap:
$1.37B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-7.5659
EPS:
-2.58
Net Cash Flow:
$-159.66M
1W Performance:
-5.75%
1M Performance:
+29.02%
6M Performance:
-25.55%
1Y Performance:
-52.63%
1-Day Range:
$18.00
$19.94
1-Week Range:
$17.85
$21.23
52-Week Range:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
19.52 | 1.37B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Celldex: Q1 Earnings Snapshot - MySA
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Celldex Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Loss $0.81 Per Share, vs. FactSet Est of $-0.75 - marketscreener.com
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - Bluefield Daily Telegraph
Stock Market Recap: Celldex Therapeutics Inc (CLDX) Concludes at 18.40, a -9.31 Surge/Decline - DWinneX
Cantor Fitzgerald maintains Celldex stock Overweight with $67 target By Investing.com - Investing.com Canada
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating fro - GuruFocus
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock News - GuruFocus
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - The Manila Times
New Clinical Data Reveals Breakthrough Potential for Celldex's EoE Treatment at Major Medical Conference - Stock Titan
Celldex: Q4 Earnings Snapshot - Barchart.com
Market Insights: Celldex Therapeutics Inc (CLDX)’s Notable Drop of -0.58, Closing at 20.71 - DWinneX
A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Sete News
Invesco Ltd. Has $1.06 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Celldex Therapeutics Inc’s results are impressive - uspostnews.com
The Attractiveness of Investing In Celldex Therapeutics Inc (CLDX) is Growing - knoxdaily.com
Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
Canaccord Genuity Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target - marketscreener.com
Canaccord Initiates Coverage on Celldex (CLDX) with a Positive O - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Celldex Therapeutics Inc [CLDX] Records 200-Day SMA of $28.24 - knoxdaily.com
Regeneron Pharmaceuticals, Inc [REGN] Shares Rise 0.40 % on Wednesday - knoxdaily.com
How to interpret Celldex Therapeutics Inc (CLDX)’s stock chart patterns - uspostnews.com
Chronic Spontaneous Urticaria Market Set for Robust Growth From - openPR.com
Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (NASDAQ:CLDX) - Seeking Alpha
Commit To Purchase Celldex Therapeutics At $15, Earn 20.1% Annualized Using Options - Nasdaq
Urticaria Pipeline: 20+ Innovators Driving the Next Wave of Advanced Treatment Options | DelveInsight - openPR.com
Vanguard Group Inc. Acquires 12,213 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex stock touches 52-week low at $14.57 amid market challenges - Investing.com Australia
Celldex stock touches 52-week low at $14.57 amid market challenges By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Takes $306,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Corebridge Financial Inc. Reduces Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Detailed In New Research Report - openPR.com
Celldex Therapeutics Enters Oversold Territory (CLDX) - Nasdaq
Teacher Retirement System of Texas Buys 2,819 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex stock touches 52-week low at $18.52 amid market challenges - Investing.com Philippines
Celldex stock touches 52-week low at $18.52 amid market challenges By Investing.com - Investing.com South Africa
When (CLDX) Moves Investors should Listen - news.stocktradersdaily.com
Swiss National Bank Increases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Business Outlook ,Growth - openPR.com
Hive Of ActivityCelldex To Report Long-term Results Of Urticaria Drug - RTTNews
Why Celldex Deserves Your Attention? - RTTNews
Charles Schwab Investment Management Inc. Increases Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
7 Analysts Have This To Say About Celldex Therapeutics - Benzinga
Celldex a new overweight at Morgan Stanley on urticaria candidate - Seeking Alpha
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.73%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):